Few fund managers were bullish on Sarepta Therapeutics ahead of its 45% Monday surge, judging by the dearth of positions on the stock.
Read the original post by Barron’s
Consumer Electronics in the News
Few fund managers were bullish on Sarepta Therapeutics ahead of its 45% Monday surge, judging by the dearth of positions on the stock.
Read the original post by Barron’s